Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Centaurea aegyptiaca methanolic extract is a natural product research compound derived from the aerial parts of the *Centaurea aegyptiaca* L. plant, a member of the Asteraceae family native to Egypt and the Sinai Peninsula. The extract is characterized by a complex phytochemical profile containing sixty-one phenolic compounds, including various phenolic acids, flavonols, and flavones. In preclinical academic studies, the extract has demonstrated significant in vitro cytotoxic activity against several human cancer cell lines, including hepatocellular carcinoma (Hep-G2), breast adenocarcinoma (MCF-7), colon carcinoma (HCT-116), and cervical carcinoma (HELA). It also exhibits weak antiviral activity specifically against the hepatitis A virus. Currently, research is primarily conducted within academic institutions in Egypt, such as Al-Azhar University and October University of Modern Sciences and Arts, with no evidence of commercial pharmaceutical development or clinical-stage trials.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on centaurea aegyptiaca methanolic extract.